LXRX News and Press, Lexicon Pharmaceuticals Inc. From 11/16/20

THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular death...

THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference: Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 Lonnel Coats, Lexicon’s pr...

With the closing of the sale of Xermelo, management has meaningfully reduced debt, leaving the company with no significant maturities or conversions and about $111M in quarter-end cash. Lexicon has enough cash on hand to see LX9211 through two Phase II clinical studies in pain (diabet...

Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Lexicon Pharmaceuticals Inc (LXRX) Q3 2020 Earnings Call Transc...

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2020 Earnings Conference Call October 29, 2020 8:00 AM ET Company Participants Chas Schultz – Investor Relations Lonnel Coats – President and Chief Executive Officer Praveen Tyle – Executive Vice President-Research and Development J...

Lexicon Pharmaceuticals (LXRX) Q3 results:Revenues: $6.63M (-97.7% Y/Y) vs consensus of $91.34M.XERMELO U.S. net sales were $6.5M.Net income: $82.6M (-66.7%); profit/share: $0.71 (-26.9%); Cash and Investments: $111.4M.Anticipated Near-Term Milestones: Q4 2020 – Initiation of...

Lexicon Pharmaceuticals (LXRX): Q3 EPS of $0.71 may not be comparable to consensus of $0.21.Revenue of $6.63M (-97.7% Y/Y) misses by $84.71M.Shares +5.74% PM.Press Release For further details see: Lexicon Pharmaceuticals EPS of $0.71

THE WOODLANDS, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2020 and provided an update of key milestones. “In the third quarter, we streamlined our opera...

The semiconductor industry has been hit hard by the U.S.-China trade tensions and the U.S. actions against Huawei and SMIC.In August, the U.S. Commerce Department expanded restrictions announced in May to obtain semiconductors without a special license - including chips made by foreign firms ...

THE WOODLANDS, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2020 financial results on Thursday, October 29, 2020 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ...